Literature DB >> 21656826

Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.

Lu Gan1, Jianlin Wang, Huibi Xu, Xiangliang Yang.   

Abstract

BACKGROUND: Taxane chemotherapy is one of the few therapeutic options for men with castration-resistant prostate cancer. However, the working mechanisms are not fully understood. We aimed to investigate the possible molecular mechanism of apoptosis induced by taxanes in prostate cancer.
METHODS: The human LNCaP cells (bearing wild-type p53), DU145 cells (bearing mutant p53) and PC3 cells (lacking p53) were used. The expression levels of protein were determined by Western blot and the mRNA levels were determined by reverse transcriptase PCR. The apoptosis was measured by propidium iodide (PI) staining and flow cytometric analysis.
RESULTS: LNCaP cells are more resistant to docetaxel than DU145 and PC3 cells. Knocking down p53 by small interference RNA (siRNA) sensitizes LNCaP cells to docetaxel treatment. Docetaxel stabilizes p53 protein level and upregulates p21 in a p53-dependent manner in LNCaP cells. Docetaxel increases p38 phosphorylation in LNCaP cells. Treatment with p38-specific inhibitor SB203580 or knocking down p38 by siRNA significantly impaired the upregulation of p53 and p21 by docetaxel. Knocking down p38 or p21 sensitizes LNCaP cells to docetaxel treatment and the antiapoptotic effect of p21 can be reversed by p38 siRNA in LNCaP cells.
CONCLUSIONS: Stimulation of the p38/p53/p21 signaling axis could be important for regulating the susceptibility towards docetaxel in prostate cancer.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656826     DOI: 10.1002/pros.21331

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  41 in total

Review 1.  Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

Authors:  Cameron M Armstrong; Allen C Gao
Journal:  Am J Clin Exp Urol       Date:  2015-08-08

2.  Regulation of paclitaxel sensitivity in prostate cancer cells by PTEN/maspin signaling.

Authors:  Yu Gan; Qing Chen; Yan Lei
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

3.  Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth.

Authors:  Rodrigo Esaki Tamura; Marlous G Lana; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  Gene Ther       Date:  2019-03-29       Impact factor: 5.250

4.  Induction of protective autophagy against apoptosis in HepG2 cells by isoniazid independent of the p38 signaling pathway.

Authors:  Tian-Guang Zhang; Yi-Mei Wang; Jun Zhao; Ming-Yu Xia; Shuang-Qing Peng; Takashi Ikejima
Journal:  Toxicol Res (Camb)       Date:  2016-04-04       Impact factor: 3.524

5.  Correlating phosphoproteomic signaling with castration resistant prostate cancer survival through regression analysis.

Authors:  Reynald Lescarbeau; David L Kaplan
Journal:  Mol Biosyst       Date:  2014-01-10

6.  Phosphorylation Impacts N-end Rule Degradation of the Proteolytically Activated Form of BMX Kinase.

Authors:  Mohamed A Eldeeb; Richard P Fahlman
Journal:  J Biol Chem       Date:  2016-09-06       Impact factor: 5.157

7.  MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.

Authors:  Cameron M Armstrong; Chengfei Liu; Wei Lou; Alan P Lombard; Christopher P Evans; Allen C Gao
Journal:  Prostate       Date:  2017-06       Impact factor: 4.104

Review 8.  Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death.

Authors:  Kannan Badri Narayanan; Manaf Ali; Barry J Barclay; Qiang Shawn Cheng; Leandro D'Abronzo; Rita Dornetshuber-Fleiss; Paramita M Ghosh; Michael J Gonzalez Guzman; Tae-Jin Lee; Po Sing Leung; Lin Li; Suidjit Luanpitpong; Edward Ratovitski; Yon Rojanasakul; Maria Fiammetta Romano; Simona Romano; Ranjeet K Sinha; Clement Yedjou; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Dustin G Brown; Elizabeth P Ryan; Annamaria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Hosni K Salem; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Seo Yun Kim; William H Bisson; Leroy Lowe; Hyun Ho Park
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

9.  Maintaining a regular physical activity aggravates intramuscular tumor growth in an orthotopic liposarcoma model.

Authors:  Mohamad Assi; Frédéric Derbré; Luz Lefeuvre-Orfila; Dany Saligaut; Nathalie Stock; Mickael Ropars; Amélie Rébillard
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

10.  Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer.

Authors:  Dong-Rong Yang; Xian-Fan Ding; Jie Luo; Yu-Xi Shan; Ronghao Wang; Shin-Jen Lin; Gonghui Li; Chiung-Kuei Huang; Jin Zhu; Yuhchyau Chen; Soo Ok Lee; Chawnshang Chang
Journal:  J Biol Chem       Date:  2013-04-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.